comparemela.com
  1. Home
  2. Live Updates
  3. Luoxin Pharmaceuticals Group Stock Co Ltd - Breaking News

Latest Breaking News On - Luoxin pharmaceuticals group stock co ltd - Page 1 : comparemela.com

Luoxin Pharmaceutical s LX-039 (Innovative Anti-Tumor Drug): Phase I Clinical Study Data Presented at ESMO 2023

/PRNewswire/ From October 20 to 24, the 2023 ESMO Congress was held in Madrid, Spain. LX-039, an innovative anti-tumor drug developed by Luoxin.

Luoxin pharmaNational torch planLuoxin pharmaceutical group stock co ltdClinical cancer researchTechnology innovation model enterpriseFudan university shanghai cancer centerNational major new product planChinese pharmaceutical enterprisesNational industrial quality model enterpriseLuoxin pharmaceuticals group stock co ltdLuoxin pharmaceuticalProfessor hu xichunFudan university shanghai cancerLouxin pharmaceuticalCancer researchPharmaceutical enterprises

Luoxin Pharmaceuticals Group Stock Co , Ltd s LX-039 (Innovative Anti-Tumor Drug) Phase I Clinical Study Data Presented At ESMO 2023

From October 20 to 24, the 2023 ESMO Congress was held in Madrid, Spain. LX-039, an innovative anti-tumor drug developed by Luoxin Pharmaceuticals Group Stock Co., Ltd. , was selected for poster.

Fudan university shanghai cancer centerLuoxin pharmaceuticals group stock co ltdFrom octoberLuoxin pharmaceuticalProfessor hu xichunFudan university shanghai cancerLouxin pharmaceutical

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.